Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
2021 · Nature Medicine · 270 citations
https://doi.org/10.1038/s41591-021-01488-2
R
Rebecca Kruisselbrink
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
30
Papers
1.4K
Citations
13
h-index
14
i10-index
Rebecca Kruisselbrink is an academic researcher from McMaster University. The author has contributed to research in topics: COVID-19 Clinical Research Studies & Long-Term Effects of COVID-19 & Sepsis Diagnosis and Treatment. The author has an h-index of 13, co-authored 26 publications.
Papers by this author
worksEffect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19
2021 · JAMA · 209 citations
https://doi.org/10.1001/jama.2021.18178
Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19
2022 · JAMA · 149 citations
https://doi.org/10.1001/jama.2022.2910
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial
2022 · JAMA · 134 citations
https://doi.org/10.1001/jama.2022.23257
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
2021 · Intensive Care Medicine · 96 citations
https://doi.org/10.1007/s00134-021-06448-5
Intravenous Vitamin C for Patients Hospitalized With COVID-19
2023 · JAMA · 45 citations
https://doi.org/10.1001/jama.2023.21407
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat